The company blamed a regulatory setback affecting development of its lead U.S. drug candidate linzagolix for uterine fibroids (UF), for which a new drug application (NDA) has been filed with the FDA. Linzagolix is a novel, once-daily, oral gonadotropin releasing hormone (GnRH) receptor antagonist designed to treat heavy menstrual bleeding associated with UF as well as pain associated with endometriosis . . .
- Allergic Diseases
- Neurological Disorders
- Alzheimers
- Virology
- Coronavirus
- Financing
- GEN Edge
- Translational Medicine
- Infectious Diseases
- Women's Health
StockWatch: ObsEva Shares Crumble on Layoff Plans after FDA ‘Review Issues’
Cassava, Revelation see stock selloffs; AlloVir rises on $126.6M offering; InflaRx jumps on EUA submission plans
Credit: triloks / Getty Images